Here’s a five-step and vendor-agnostic road map to building AI-driven insights that customers and regulators can believe in.
Netherlands-based argenx has published positive topline results from its ADAPT SERON trial of its market-leading drug for generalised myasthenia gravis (gMG) Vyvgart (efgartigimod). Significantly, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback